Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/30107
THE HUMAN HOOKWORM VACCINE
Author
Affilliation
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA /Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA / Department of Pediatrics and Molecular Virology and Microbiology. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Department of Microbiology, Immunology, and Tropical Medicine. George Washington University School of Medicine and Health Sciences. Washington, DC, USA.
Public Health Computational and Operations Research. University of Pittsburgh School of Medicine. Pittsburgh, PA, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA / Department of Pediatrics and Molecular Virology and Microbiology. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Department of Microbiology, Immunology, and Tropical Medicine. George Washington University School of Medicine and Health Sciences. Washington, DC, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA / Department of Pediatrics and Molecular Virology and Microbiology. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA.
Faculty of Infectious and Tropical Disease. London School of Hygiene and Tropical Medicine. UK.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Public Health Computational and Operations Research. University of Pittsburgh School of Medicine. Pittsburgh, PA, USA.
Queensland Tropical Health Alliance. James Cook University. Cairns, Australia.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, United States/Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA.
Fundação Oswaldo Cruz. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa René Rachou. Belo Horizonte, MG, Brasil.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Department of Microbiology, Immunology, and Tropical Medicine. George Washington University School of Medicine and Health Sciences. Washington, DC, USA.
Public Health Computational and Operations Research. University of Pittsburgh School of Medicine. Pittsburgh, PA, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA / Department of Pediatrics and Molecular Virology and Microbiology. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Department of Microbiology, Immunology, and Tropical Medicine. George Washington University School of Medicine and Health Sciences. Washington, DC, USA.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA / Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA / Department of Pediatrics and Molecular Virology and Microbiology. National School of Tropical Medicine. Baylor College of Medicine. Houston, TX, USA.
Faculty of Infectious and Tropical Disease. London School of Hygiene and Tropical Medicine. UK.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Rio de Janeiro, Brasil.
Public Health Computational and Operations Research. University of Pittsburgh School of Medicine. Pittsburgh, PA, USA.
Queensland Tropical Health Alliance. James Cook University. Cairns, Australia.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, United States/Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA.
Fundação Oswaldo Cruz. Rio de Janeiro, Brasil.
Fundação Oswaldo Cruz. Centro de Pesquisa René Rachou. Belo Horizonte, MG, Brasil.
Sabin Vaccine Institute Product Development Partnership. Houston, TX, USA / Sabin Vaccine Institute Product Development Partnership. Washington, DC, USA.
Abstract
Hookworm infection is one of the world's most common neglected tropical diseases and a leading cause of iron deficiency anemia in low- and middle-income countries. A Human Hookworm Vaccine is currently being developed by the Sabin Vaccine Institute and is in phase 1 clinical testing. The candidate vaccine is comprised of two recombinant antigens known as Na-GST-1 and Na-APR-1, each of which is an important parasite enzyme required for hookworms to successfully utilize host blood as a source of energy. The recombinant proteins are formulated on Alhydrogel(®) and are being tested in combination with a synthetic Toll-like receptor 4 agonist. The aim of the vaccine is to induce anti-enzyme antibodies that will reduce both host blood loss and the number of hookworms attached to the gut. Transfer of the manufacturing technology to the Oswaldo Cruz Foundation (FIOCRUZ)/Bio-Manguinhos (a Brazilian public sector developing country vaccine manufacturer) is planned, with a clinical development plan that could lead to registration of the vaccine in Brazil. The vaccine would also need to be introduced in the poorest regions of Africa and Asia, where hookworm infection is highly endemic. Ultimately, the vaccine could become an essential tool for achieving hookworm control and elimination, a key target in the 2012 London Declaration on Neglected Tropical Diseases.
Share